ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 09-30. Amounts in USD.

Revenue TTM

0 400M 800M 1.2B Q4 '11: 296.1K Q1 '12: 24K Q2 '12: 55.2K Q3 '12: 103.1K Q4 '12: 146.9K Q1 '13: 281.9K Q2 '13: 294.4K Q3 '13: 290.3K Q4 '13: 290.3K Q1 '14: 175K Q2 '14: 175K Q3 '14: 175K Q4 '14: 175K Q1 '15: 302K Q2 '15: 302K Q3 '15: 382K Q4 '15: 382K Q1 '16: 255K Q2 '16: 255K Q3 '16: 170.8K Q4 '16: 158.3K Q1 '17: 4.5M Q2 '17: 13.4M Q3 '17: 22.7M Q4 '17: 31.4M Q1 '18: 30.6M Q2 '18: 22.2M Q3 '18: 13.6M Q4 '18: 16.1M Q1 '19: 47.3M Q2 '19: 94.8M Q3 '19: 136.8M Q4 '19: 168.8M Q1 '20: 163.6M Q2 '20: 139M Q3 '20: 123.7M Q4 '20: 88M Q1 '21: 79.8M Q2 '21: 89.1M Q3 '21: 107.6M Q4 '21: 138.3M Q1 '22: 144.4M Q2 '22: 263.4M Q3 '22: 249.9M Q4 '22: 243.2M Q1 '23: 278.3M Q2 '23: 272.8M Q3 '23: 256.2M Q4 '23: 240.7M Q1 '24: 181.7M Q2 '24: 35.5M Q3 '24: 19.6M Q4 '24: 3.6M Q1 '25: 2.5M Q2 '25: 545.2M Q3 '25: 573M Q4 '25: 829.4M Q1 '26: 1.1B Q2 '26: 622M Q3 '26: 669.5M Q3 '12 Q3 '14 Q3 '16 Q3 '18 Q3 '20 Q3 '22 Q3 '24 Q3 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-750M -500M -250M 0 250M 500M 750M Q2 '11: -8.3M Q3 '11: -8.7M Q4 '11: -9.8M Q1 '12: -10.5M Q2 '12: -13.6M Q3 '12: -18.6M Q4 '12: -21.1M Q1 '13: -21.9M Q2 '13: -22.4M Q3 '13: -22M Q4 '13: -24.6M Q1 '14: -26.8M Q2 '14: -32.6M Q3 '14: -38.9M Q4 '14: -53.3M Q1 '15: -71.4M Q2 '15: -89.8M Q3 '15: -93.1M Q4 '15: -96M Q1 '16: -90.2M Q2 '16: -81.8M Q3 '16: -85.2M Q4 '16: -81.7M Q1 '17: -77.3M Q2 '17: -62.2M Q3 '17: -48.5M Q4 '17: -37M Q1 '18: -35.9M Q2 '18: -44.8M Q3 '18: -55M Q4 '18: -55.9M Q1 '19: -31.2M Q2 '19: 5.9M Q3 '19: 40.4M Q4 '19: 61.2M Q1 '20: 45.4M Q2 '20: 1.1M Q3 '20: -33.4M Q4 '20: -93.2M Q1 '21: -112.4M Q2 '21: -118.4M Q3 '21: -134.3M Q4 '21: -149M Q1 '22: -188.3M Q2 '22: -118.5M Q3 '22: -159.6M Q4 '22: -178.5M Q1 '23: -157.3M Q2 '23: -150.7M Q3 '23: -180.5M Q4 '23: -205M Q1 '24: -299.4M Q2 '24: -473.8M Q3 '24: -547.2M Q4 '24: -601.1M Q1 '25: -625.9M Q2 '25: -118.6M Q3 '25: -108M Q4 '25: 98.3M Q1 '26: 300.6M Q2 '26: -221.9M Q3 '26: -226.4M Q3 '12 Q3 '14 Q3 '16 Q3 '18 Q3 '20 Q3 '22 Q3 '24 Q3 '26

Net Income TTM

-750M -500M -250M 0 250M 500M 750M Q2 '11: -907.6K Q3 '11: -2.4M Q4 '11: -3.1M Q1 '12: -4.2M Q2 '12: -12.4M Q3 '12: -18.6M Q4 '12: -21.1M Q1 '13: -23.3M Q2 '13: -24.7M Q3 '13: -22.8M Q4 '13: -31.1M Q1 '14: -37.2M Q2 '14: -44.3M Q3 '14: -49.9M Q4 '14: -58.6M Q1 '15: -70.6M Q2 '15: -85.3M Q3 '15: -89.6M Q4 '15: -91.9M Q1 '16: -88.6M Q2 '16: -80.8M Q3 '16: -84.2M Q4 '16: -81.7M Q1 '17: -74.5M Q2 '17: -59.8M Q3 '17: -45.9M Q4 '17: -34.4M Q1 '18: -35.5M Q2 '18: -44.3M Q3 '18: -54.4M Q4 '18: -54.5M Q1 '19: -29.2M Q2 '19: 9.6M Q3 '19: 45.5M Q4 '19: 68M Q1 '20: 53.3M Q2 '20: 9.5M Q3 '20: -24.4M Q4 '20: -84.6M Q1 '21: -102.6M Q2 '21: -109.6M Q3 '21: -125.9M Q4 '21: -140.8M Q1 '22: -183M Q2 '22: -111.8M Q3 '22: -153.9M Q4 '22: -176.1M Q1 '23: -154.5M Q2 '23: -150.2M Q3 '23: -181.1M Q4 '23: -205.3M Q1 '24: -296.8M Q2 '24: -470.8M Q3 '24: -538.6M Q4 '24: -599.5M Q1 '25: -639.7M Q2 '25: -144M Q3 '25: -148.4M Q4 '25: -1.6M Q1 '26: 202.3M Q2 '26: -300.9M Q3 '26: -320M Q3 '12 Q3 '14 Q3 '16 Q3 '18 Q3 '20 Q3 '22 Q3 '24 Q3 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-600M -400M -200M 0 200M 400M 600M Q3 '11: -7.9M Q4 '11: -7.7M Q1 '12: -9.5M Q2 '12: -9.5M Q3 '12: -12.4M Q4 '12: -15.3M Q1 '13: -16.5M Q2 '13: -16.8M Q3 '13: -18.2M Q4 '13: -19M Q1 '14: -22.2M Q2 '14: -25.4M Q3 '14: -29.9M Q4 '14: -35.4M Q1 '15: -52.6M Q2 '15: -61.3M Q3 '15: -64.6M Q4 '15: -65.7M Q1 '16: -62.7M Q2 '16: -61M Q3 '16: -66.3M Q4 '16: -64.4M Q1 '17: -33.3M Q2 '17: -32.9M Q3 '17: -24.9M Q4 '17: -23.9M Q1 '18: -48.6M Q2 '18: -49.7M Q3 '18: -53.7M Q4 '18: -47.2M Q1 '19: 135.8M Q2 '19: 131.6M Q3 '19: 156.5M Q4 '19: 173M Q1 '20: -18.8M Q2 '20: -26.8M Q3 '20: -70.7M Q4 '20: -95.8M Q1 '21: -111.2M Q2 '21: 180.3M Q3 '21: 184.1M Q4 '21: 171.3M Q1 '22: 148.9M Q2 '22: -52.2M Q3 '22: -91.4M Q4 '22: -136.1M Q1 '23: -150.3M Q2 '23: -244.7M Q3 '23: -196.7M Q4 '23: -153.9M Q1 '24: -196.2M Q2 '24: -256.9M Q3 '24: -351.6M Q4 '24: -462.9M Q1 '25: -491.3M Q2 '25: 61.1M Q3 '25: 21.8M Q4 '25: 179.6M Q1 '26: 339.3M Q2 '26: -36.3M Q3 '26: -59.1M Q3 '12 Q3 '14 Q3 '16 Q3 '18 Q3 '20 Q3 '22 Q3 '24 Q3 '26

Free Cash Flow TTM

-750M -500M -250M 0 250M 500M 750M Q2 '12: -9.8M Q3 '12: -12.8M Q4 '12: -15.8M Q1 '13: -16.9M Q2 '13: -17M Q3 '13: -18.5M Q4 '13: -19.3M Q1 '14: -22.6M Q2 '14: -26.3M Q3 '14: -31.2M Q4 '14: -37.1M Q1 '15: -54.8M Q2 '15: -63.2M Q3 '15: -66.2M Q4 '15: -67.7M Q1 '16: -64.5M Q2 '16: -62.7M Q3 '16: -68.2M Q4 '16: -68.3M Q1 '17: -42M Q2 '17: -42.9M Q3 '17: -35.4M Q4 '17: -31.9M Q1 '18: -51.4M Q2 '18: -51.5M Q3 '18: -54.6M Q4 '18: -48.6M Q1 '19: 133.7M Q2 '19: 129.8M Q3 '19: 151.7M Q4 '19: 161M Q1 '20: -34.4M Q2 '20: -45.8M Q3 '20: -88.6M Q4 '20: -107.8M Q1 '21: -123.1M Q2 '21: 164.8M Q3 '21: 166.8M Q4 '21: 147.7M Q1 '22: 123.9M Q2 '22: -74.9M Q3 '22: -119.7M Q4 '22: -188.9M Q1 '23: -236.2M Q2 '23: -353.2M Q3 '23: -342.2M Q4 '23: -330.6M Q1 '24: -402.7M Q2 '24: -470.2M Q3 '24: -532.6M Q4 '24: -604.3M Q1 '25: -571.6M Q2 '25: 9.6M Q3 '25: -17.6M Q4 '25: 156.9M Q1 '26: 322M Q2 '26: -50.9M Q3 '26: -75.1M Q3 '12 Q3 '14 Q3 '16 Q3 '18 Q3 '20 Q3 '22 Q3 '24 Q3 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q3 '10: 64.6M Q2 '11: 7.9M Q3 '11: 7.2M Q2 '12: 10.7M Q3 '12: 11.2M Q1 '18: 74.8M Q2 '18: 84.1M Q3 '18: 87.6M Q1 '19: 95.6M Q2 '19: 98.1M Q3 '19: 98.9M Q1 '20: 97.1M Q2 '20: 101.7M Q3 '20: 101.8M Q1 '21: 102.8M Q2 '21: 103.9M Q3 '21: 104.1M Q1 '22: 104.5M Q2 '22: 107.9M Q3 '22: 105.8M Q1 '23: 106M Q2 '23: 108.1M Q3 '23: 107M Q1 '24: 107.4M Q2 '24: 123.3M Q3 '24: 124.2M Q1 '25: 124.8M Q2 '25: 134.5M Q3 '25: 139M Q1 '26: 140.7M Q2 '26: 142.4M Q3 '26: 143.4M Q2 '12 Q3 '18 Q1 '20 Q2 '21 Q3 '22 Q1 '24 Q2 '25 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q2 '11: -0.64 Q3 '11: -0.88 Q4 '11: -0.40 Q1 '12: -0.49 Q2 '12: -1.36 Q3 '12: -1.82 Q4 '12: -1.88 Q1 '13: -1.96 Q2 '13: -1.87 Q3 '13: -1.39 Q4 '13: -1.40 Q1 '14: -1.35 Q2 '14: -1.25 Q3 '14: -1.24 Q4 '14: -1.23 Q1 '15: -1.36 Q2 '15: -1.56 Q3 '15: -1.61 Q4 '15: -1.61 Q1 '16: -1.52 Q2 '16: -1.36 Q3 '16: -1.41 Q4 '16: -1.33 Q1 '17: -1.18 Q2 '17: -0.91 Q3 '17: -0.66 Q4 '17: -0.46 Q1 '18: -0.47 Q2 '18: -0.57 Q3 '18: -0.68 Q4 '18: -0.66 Q1 '19: -0.35 Q2 '19: 0.07 Q3 '19: 0.46 Q4 '19: 0.70 Q1 '20: 0.54 Q2 '20: 0.10 Q3 '20: -0.24 Q4 '20: -0.84 Q1 '21: -1.01 Q2 '21: -1.07 Q3 '21: -1.23 Q4 '21: -1.36 Q1 '22: -1.76 Q2 '22: -1.09 Q3 '22: -1.48 Q4 '22: -1.68 Q1 '23: -1.47 Q2 '23: -1.43 Q3 '23: -1.71 Q4 '23: -1.92 Q1 '24: -2.77 Q2 '24: -4.24 Q3 '24: -4.66 Q4 '24: -5.01 Q1 '25: -5.16 Q2 '25: -1.39 Q3 '25: -1.27 Q4 '25: -0.01 Q1 '26: 1.60 Q2 '26: -2.08 Q3 '26: -2.18 Q3 '12 Q3 '14 Q3 '16 Q3 '18 Q3 '20 Q3 '22 Q3 '24 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.